Abstracts tagged "Biologicals"

Abstract Number: 0426 • ACR Convergence 2023
The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis
Tomokazu Choshi¹, Kenji Mamoto¹, Yutaro Yamada¹, Tadashi Okano¹, Shohei Anno², Kazuki Orita², Takahiro Iida³, Masahiro Tada⁴, Kentaro Inui⁵, Tatsuya Koike⁶ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Koryokai Hospital, Osaka, Japan, ⁴Osaka City General Hospital, Osaka, Japan, ⁵Saiseikai Nakatsu Hospital, Osaka, Japan, ⁶Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Some patients with rheumatoid arthritis (RA) need switching therapy between biologic agents (Bio) and Janus kinase inhibitors (JAKi) when efficacy of Bio or JAKi…
Abstract Number: 0537 • ACR Convergence 2023
Asynchronous Teleconsultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy as a More Sustainable Model Than Face-to-face Classical Consultation
Natalia Rivera¹, elena abad plou², Eva Galindez-Agirregoikoa³, Eduardo Cuende⁴, Ana Rosa Intxaurbe⁵, Juan M Blanco Madrigal³, Lucia Vega-Alvarez³, Carmen Lucia Garcia-Gomez⁶, Maria Enjuanes-Noguero⁷, Olaia Fernandez-Berrizbeitia⁸, Maria Rosa Exposito Molinero⁹, Maria Esther Ruiz Lucea³, Ignacio Torre Salaberri⁵, iñigo Gorostiza Hormaeche³ and Maria Luz Garcia Vivar³, ¹Biocruces Bizkaia Health Research Institute, Research area, Bilbao, Spain, ²Hospital universitario de Basurto, Bilbo, Spain, ³Basurto University Hospital, Bilbao, Spain, ⁴Basurto University Hospital, Rheumatology, Madrid, Spain, ⁵Basurto University Hospital, Rheumatology, Bilbao, Spain, ⁶Basurto University Hospital, Rheumatology, Terrassa, Spain, ⁷Hospital Universitario de Basurto, Bilbao, Spain, ⁸Spanish Health Care Service, Bilbao, Spain, ⁹Hospital de Basurto, Bilbao, Spain
Background/Purpose: Before COVID pandemic, telehealth use for the followup of rheumatic disease patients had been limited, but nowadays it appears as a more sustainable model…
Abstract Number: 0775 • ACR Convergence 2023
Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
Amy Peeters, C.A.J Michielsens, Elien Mahler, Lise Verhoef, Alfons den Broeder, Nathan den Broeder and Noortje van Herwaarden, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are effective in PsA and axial SpA, but are associated with increased infections risk, patient burden and high costs.…
Abstract Number: 1076 • ACR Convergence 2023
Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Olga Rusinovich¹, Enrique Calvo-Aranda², Claudia Maria Gomez², Patricio Cardoso Peñafiel², Pilar Navarro Alonso³, Miguel Cantalejo Moreira⁴, Alberto Diaz y Oca³, Pablo Navarro⁵, Maria Machattou⁵, Maria Alonso⁵, Carlota Navarro⁵, Carolina Merino⁵, Hilda Godoy⁶, Maria Carmen Barbadillo Mateos⁷, Carlos Isasi⁵, Maria Perez Ferro⁸, Jessica Polo⁹, Veronica Garcia¹⁰, Jose Luis Andreu-Sánchez¹¹, Jose Campos¹² and Jesus Sanz¹³, ¹Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, ²Hospital Universitario Infanta Leonor, Madrid, Spain, ³Fuenlabrada University Hospital, Madrid, Spain, ⁴Hospital Universitario de Fuenlabrada, Madrid, Spain, ⁵Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁷Public, Madrid, Spain, ⁸Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁹Rey Juan Carlos University Hospital, Madrid, Spain, ¹⁰Ramon y Cajal University Hospital, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹²Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively…
Abstract Number: 1320 • ACR Convergence 2023
Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept
Paolo Semeraro¹, Fabrizio Angeli¹, Alessia Caproli¹, Franco Franceschini², Paolo Airò³ and Silvia Piantoni⁴, ¹Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁴ASST Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Helper T cells (Th) are key players in rheumatoid arthritis (RA). Th17 and Th17.1 have a prominent function in the early phase of inflammation,…
Abstract Number: 1440 • ACR Convergence 2023
Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks
Michaela Koehm¹, Ann Christina Foldenauer², Tanja Rossmanith², Herbert Kellner³, Uta Kiltz⁴, Arnd Kleyer⁵, Gerd Burmester⁶, David Kofler⁷, Jan Brandt-Juergens⁸, Raoul Bergner⁹ and Frank Behrens¹⁰, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁷University of Cologne, Cologne, Germany, ⁸rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Municipal Hospital Ludwigshafen, Department of Internal Medicine A, Nephrology and Rheumatology, Ludwigshafen, Germany, ¹⁰Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD therapy in active psoriatic arthritis (PsA). The value of MTX in combination with different bDMARDs is…
Abstract Number: 1697 • ACR Convergence 2023
Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
Ioannis Parodis¹, Julius Lindblom¹, Guillermo Barturen², Rafaela Ortega Castro³, Ricard Cervera⁴, Jacques-Olivier Pers⁵, Fernanda Genre Romero⁶, Falk Hiepe⁷, Maria Gerosa⁸, Laszlo Kovacs⁹, Ellen De Langhe¹⁰, Silvia Piantoni¹¹, Georg Stummvoll¹², Carlos Vasconcelos¹³, Barbara Vigone¹⁴, Torsten Witte¹⁵, Marta Alarcon-Riquelme¹⁶ and Lorenzo Beretta¹⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France, ⁶IDIVAL, Santander, Spain, ⁷Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁸University of Milan, Milano, Italy, ⁹University of Szeged, Szeged, Hungary, ¹⁰Katholieke Universiteit Leuven and Universitair Ziekenhuis Leuven, Leuven, Belgium, ¹¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹²Medical University Vienna, Baden, Austria, ¹³Centro Hospitalar do Porto, Porto, Portugal, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁵Dept of Immunology and Rheumatology, Hannover, Germany, ¹⁶Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Treating to remission or lupus low disease activity state (LLDAS) are conceptual frameworks for the management of SLE, but the biological milieus underlying these…
Abstract Number: 2154 • ACR Convergence 2023
Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs
Sebastian Ibanez Vodnizza¹, María Paz Poblete², María Francisca Valenzuela³, María Magdalena Canals², Dominga García² and Carla Jaque³, ¹Clinica Alemana de Santiago / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ²Hospital Padre Hurtado / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ³Hospital Padre Hurtado, Santiago, Chile
Background/Purpose: In Chile, patients with rheumatoid arthritis (RA) can apply to receive state-funded biological or JAK inhibitor treatment if they have failed (defined as a…
Abstract Number: 2241 • ACR Convergence 2023
Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielman², Jacques-Eric Gottenberg³, Pierre-Marie Duret², Emmanouil Rampakakis⁴, Mohamed Sharaf⁵, Caren Constantin⁶, vincenza campana⁶ and Laurent Messer⁷, ¹Hôpital de Hautepierre, Strasbourg, France, ²Hôpitaux civils de Colmar, Colmar, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁴JSS Medical Research, Saint-Laurent, QC, Canada, ⁵Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁶Janssen Cilag Medical Affairs, Issy les Moulineaux, France, ⁷Laboratoire Interdisciplinaire en études culturelles (LinCS), Strasbourg, France
Background/Purpose: Patients (pts) with psoriasis (PsO) or PsA are at increased risk for developing gout; and hyperuricemia (HU) prevalence is higher in PsO/PsA pts than…
Abstract Number: 2433 • ACR Convergence 2023
Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells
Gregg Silverman¹, William Rigby², Helena Jun¹, Jasmine Shwetar¹, Katie Tumang¹, Sergei Koralov³, Ellie Ivanova¹, David Mieles¹, Sladjana Skopelia-Gardner⁴ and Kelly Ruggles¹, ¹NYU Grossman School of Medicine, New York, NY, ²Hitchcock-Dartmouth Medicine Center, Hanover, NH, ³NYU Grossman Schoolof Medicine, New York, NY, ⁴Hitchcock-Dartmouth Medicine Center, Lebanon, NH
Background/Purpose: Biologic agents of diverse molecular mechanisms of action are approved for RA, but we do not have a full understanding of the implications of…
Abstract Number: 0274 • ACR Convergence 2023
A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab
Nathalie Amiable¹, Mehdi Benlarbi², Mathieu Dube³, Sonia Theriault⁴, Alexandra Godbout¹, Anne-Sophie Julien⁵, Gloria-Gabrielle Ortega-Delgado⁶, Melina Duchesne⁷, Rose Cloutier⁸, Josee Perreault⁹, Annie Gravel¹⁰, Lison Fournier¹¹, Giuliana Alfonso¹², Josiane Bourre-Tessier¹³, Marie Hudson¹⁴, Nicolas Richard¹⁵, Jean-Paul Makhzoum¹⁶, Arielle Mendel¹⁷, Sasha Bernatsky¹², Marc Dionne¹⁸, Michael Libman¹⁹, Gaston De Serres²⁰, Mélanie Dieudé²¹, louis Flamand²², Daniel Kaufmann²³, Andrés Finzi²⁴, Renée Bazin²⁵, Ines Colmegna²⁶ and Paul R. Fortin²⁷, ¹Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ²CRCHUM, Université de Montréal, Montreal, QC, Canada, ³Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁶Centre de Recherche du CHUM, Montreal, QC, Canada, ⁷Centre de recherche du Centre Hospitalier de l'Universitaire de Montréal, Montreal, QC, Canada, ⁸Centre de recherche hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁹Hema-Quebec, Quebec City, QC, Canada, ¹⁰CHU de Québec - CHUL Axe des Maladies Infectieuses et Immunitaires, Quebec City, QC, Canada, ¹¹Centre de recherche du CHU de Quebec - Université Laval, Quebec City, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ¹⁴McGill University, Montréal, QC, Canada, ¹⁵Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁶Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹⁷McGill University Health Centre, Montréal, QC, Canada, ¹⁸Centre de recherche du CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁹McGill Centre for Viral Diseases, Montreal, QC, Canada, ²⁰Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ²¹Microbiology, Infectiology and Immunology Department, Faculty of Medicine, Université de Montréal, CHUM Research Center, Héma-Québec, Montreal, QC, Canada, ²²Centre ARThrite - CHU de Quebec - Université Laval, Quebec City, QC, Canada, ²³University of Montreal, University of Lausanne, Lausanne University Hospital, Montreal, QC, Canada, ²⁴Université de Montréal, Montreal, QC, Canada, ²⁵Héma-Québec, Affaires Médicales et Innovation, Quebec City, QC, Canada, ²⁶The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada
Background/Purpose: Patients with rheumatic diseases (RD) on rituximab (RTX) have increased mortality following COVID-19 and reduced antibody response post-vaccine. We tested whether a mix-and-match strategy…
Abstract Number: 0428 • ACR Convergence 2023
Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk², Orit Schieir³, Marie-France Valois⁴, Susan Bartlett⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Edward Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Diane Tin¹², Glen Hazlewood¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹³, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York, NY, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Manitoba, Manitoba, MB, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Centre of Arthritis Excellence, Newmarket, ON, Canada, ¹³CATCH, Toronto, ON, Canada
Background/Purpose: Recent Canadian treatment recommendations suggest offering to taper of biologic or targeted synthetic therapy to patients with rheumatoid arthritis (RA) after they achieve sustained…
Abstract Number: 0539 • ACR Convergence 2023
Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis
Maxime Dougados¹, David Bulbin², Heather Jones³, Tianming Gao⁴, Anna Shmagel⁵, Thomas Poznanski⁶, Abhijeet Danve⁷ and Karl Gaffney⁸, ¹Université de Paris, Paris, France, ²Geisinger Health System, Danville, PA, ³AbbVie, Inc., Mettawa, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Long Grove, IL, ⁶AbbVie, Inc., Plainfield, IL, ⁷Yale University, New Haven, CT, ⁸Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom
Background/Purpose: Axial SpA (axSpA) and FM manifest with overlapping clinical features such as pain, fatigue, and stiffness, yet their treatment is distinctly different. FM is…
Abstract Number: 0776 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
Alan Kivitz¹, Liliana Sedova², Melvin Churchill³, Roshan Kotha⁴, Atul Singhal⁵, Alexander Torres⁶, Guillermo Valenzuela⁷, Sarah Whelan⁸, Thomas Dumortier⁹, Xuan Zhu¹⁰, Ruvie Martin¹⁰ and Luminita Pricop¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institute of Rheumatology, Prague, Czech Republic, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Sharp Community Medical Group, La Mesa, CA, ⁵Southwest Arthritis Research Group, Mesquite, TX, ⁶Highlands Advanced Rheumatology and Arthritis Center, Avon Park, FL, ⁷Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁸Novartis Ireland Ltd, Dublin, Ireland, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: To investigate the long-term efficacy, safety, and tolerability of intravenous (IV) secukinumab (SEC) in patients with active psoriatic arthritis (PsA) through 52 weeks.Methods: INVIGORATE-2…
Abstract Number: 1077 • ACR Convergence 2023
Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab
Zohra Layegh¹, Pascal de Jong¹, Sadaf Atiqi², Floris loeff³, lisanne Dijk³, Gaelle vaz³, radboud J.e.m. Dolhain⁴, Theo Rispens³ and Gertjan Wolbink⁵, ¹Erasmus medical center, Rotterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB, Amsterdam, Netherlands, ³Sanquin Diagnostic Service, Biologics Laboratory, Amsterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: Due to better effectiveness and longer drug survival, a TNF inhibitor (TNFi) should preferably be combined with methotrexate (MTX). MTX has been found to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].